ACT Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

ACT Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.77M	Sell	7,833 -500	-6%	-$123K	2.44%	13
2022 Q2	$1.57M	Hold	8,333	–	–	2.2%	11
2022 Q1	$2.08M	Buy	8,333 +3,050	+58%	+$482K	2.2%	11
2021 Q4	$823K	Hold	5,283	–	–	0.6%	32
2021 Q3	$1.06M	Hold	5,283	–	–	0.55%	35
2021 Q2	$1.35M	Buy	+5,283	New	+$1.32M	0.69%	32

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

ACT Capital Management's EIGR Position: Q3 2022 in Review

ACT Capital Management reduced its Eiger BioPharmaceuticals, Inc. (EIGR) stake by 6% in Q3 2022, selling an estimated $123K and leaving 7,833 shares worth $1.77M. The position accounts for 2.44% of the portfolio, ranked #13.

ACT Capital Management first reported a position in EIGR in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.08M in Q1 2022. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2022.

ACT Capital Management held 7,833 shares of Eiger BioPharmaceuticals, Inc. worth $1.77M as of Q3 2022.
ACT Capital Management sold 500 Eiger BioPharmaceuticals, Inc. shares in Q3 2022, an estimated $123K.
Eiger BioPharmaceuticals, Inc. made up 2.44% of ACT Capital Management's portfolio in Q3 2022, its #13 holding.
ACT Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2021 and has held it in 6 quarters since.
ACT Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $2.08M in Q1 2022.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.